Trials / Completed
CompletedNCT00652080
An Open-Label Safety Study of API 31510 in a Topical Cream for in Situ Cutaneous Squamous Cell Carcinoma (SCCIS)
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- BPGbio · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and tolerability of pharmaceutical compound 31510 in a topical cream when applied to in situ cutaneous squamous cell carcinoma and to obtain preliminary efficacy data for the treatment of in situ cutaneous squamous cell carcinoma by Compound 31510 topical cream.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | API 31510 | Topical Cream; 3% active; AM \& PM application |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2010-01-01
- Completion
- 2010-01-01
- First posted
- 2008-04-03
- Last updated
- 2019-03-05
- Results posted
- 2019-02-15
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00652080. Inclusion in this directory is not an endorsement.